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Background: Patients with atrial fibrillation (AF) are at increased risk for stroke. Antithrombotic treatment reduces
this risk. Antithrombotic treatment consists of either administration of oral anticoagulants (OAC) or the provision of
an antiplatelet drug. International guidelines provide advice on the preferred treatment, thereby balancing the risks
and benefits of OAC. However, adherence to these guidelines is reported to be as low as 50%. There is paucity in
research on why adherence rates are low. Recent studies have shown decision support systems can improve
guideline adherence. We investigate the use of a clinical decision support system to improve guideline adherence
among general practitioners (GPs) treating patients with AF and study reasons for guideline non-adherence.
Methods/Design: The study is a randomized controlled trial, which is performed among Dutch general
practitioners. Initially, GPs in the vicinity of the Academic Medical Center (AMC) in Amsterdam will be included, after
which other practices will be recruited. We have developed a novel decision support system that displays a list with
pending messages for the on-screen medical record in real time. Messages are generated on a server that evaluates
a decision rule based on the atrial fibrillation guideline of the Dutch College of General Practitioners. By interacting
with the list, messages can be opened for a description and explanation, or be ignored. GPs are allocated into three
groups: 1) control group; 2) intervention group A, in which messages can be ignored without justification; and 3)
intervention group B, in which messages can only be ignored with justification.
Our main outcome measure is the between-group difference in the proportion of patients receiving antithrombotic
prescriptions in adherence to the Dutch GP guideline for atrial fibrillation. Secondary outcomes are reasons GPs
state for deviating from the guideline and the effect on guideline adherence of requiring justification when
ignoring a message.
Discussion: This paper describes the protocol for a cluster randomized trial to study the effects of a clinical
decision support system in patients with atrial fibrillation. The system is characterized by a non-interruptive
presentation and real-time messages that are updated after each relevant action the GP performs.
Trial registration: This trial is registered with the Dutch Trial Register under registration number 3570.
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Patients with atrial fibrillation (AF) are at high risk for
stroke, with up to a fivefold risk compared to patients
without AF [1]. Apart from the increased risk, stroke se-
verity is increased [2]. Therefore, patients with AF need to
be treated with antithrombotic medication to reduce
stroke risk. Oral anticoagulants (OAC), such as warfarin
and the new oral anticoagulants (for example, dabigatran),
reduce the risk of stroke by 60%, whereas antiplatelet
drugs reduce the risk by 20% [3,4]. Because OAC increases
the risk of bleeding, not every patient is eligible for this
treatment, as there are patients with a pre-existing in-
creased risk of bleeding. Guidelines have been developed
to help the physician decide which treatment is appropri-
ate for a patient. These guidelines incorporate contraindi-
cations for OAC, and stroke risk stratification schemes to
balance risks and benefits. Estimates of current adherence
to stroke risk guidelines in the prevention of stroke in pa-
tients with atrial fibrillation is about 50% internationally,
leading to both over- and undertreatment. This is true for
both primary and secondary care [5-7]. Research on the
reasons for these low adherence rates is lacking. We
hypothesize that patient preference and medical context,
lack of time and lack of overview are important drivers in
this process. These are reasons that have been shown to
influence guideline adherence in general in previous stud-
ies [8]. More insight into the reasons stated by physicians
for non-adherence could prove valuable for future re-
search and guideline development.
The aim of this study is to investigate the effect of a
clinical decision support system (CDSS) on adherence to
the guideline that recommends antithrombotic treatment
for stroke prevention for patients with atrial fibrillation.
Clinical decision support systems have proven to be effect-
ive interventions for improving various healthcare pro-
cesses [9,10]. However, evidence for clinical improvement
is sparse [9]. We hope to expand the current body of
evidence for the effectiveness of CDSS with findings of
increased guideline adherence and, in follow-up projects,
better clinical outcomes. Furthermore, not all instances of
non-adherence are undesirable. Physicians may have good
clinical reasons (for example, comorbidity, social environ-
ment) to deviate from recommended treatment. There-
fore, the second objective of this study is to study reasons
for deviation. Lastly, we would like to evaluate whether
the requirement for justification influences response to a
clinical decision support system.
Methods/Design
This study will be a cluster randomized controlled trial.
Randomization at the patient level was considered, but
deemed inapplicable due to the fact that one GP would
have patients in both the control and intervention
groups, thus leading to possible contamination bias.Randomization at the GP level was not possible because
most GPs work in group practices and share patients,
which would lead to a GP in the control group reading
the reports of another GP who had received the inter-
vention. This would also lead to contamination bias. It
was therefore decided to randomize on the GP cluster
level, where GPs treating the same patients will be
regarded as a randomization unit (usually two or three
GPs).
GPs will be allocated into one of the following three
groups:
1. Will receive no messages (control group)
2. Will receive messages that can be ignored without
justification (intervention 1)
3. Will receive messages that can only be ignored with
justification (intervention 2)
Intervention
We have developed a plugin (an extra piece of software
that is not an integral part of the main system) for a sin-
gle GP electronic health records system (EHRS). The
CDSS plugin can be classified as active (it does not wait
to be asked), non-interruptive (does not interrupt the
workflow), and critiquing (provides feedback based on
the current treatment scheme). The basic functionality
of this decision support system is based on detecting
relevant events based on triggers, evaluating the events
and responding to them. Several trigger points in the
GPs’ EHR have been designed. Trigger points are events
that may occur in a system that then trigger an action
(for instance ‘Closing a record’= > ‘send data to the server’).
These triggers are:
1. opening a patient’s electronic medical record on the
computer
2. adding laboratory data (for example, a new
glomerular filtration rate (GFR))
3. changing medication (for example, prescribing
aspirin)
4. updating the patient’s problem list (for example,
registering a diagnosis of atrial fibrillation)
Whenever a trigger is activated, information from the
on-screen medical record (the medical record that is
currently opened on the GP’s screen) is sent to a remote
server via a secure Internet connection. This information
consists of recent laboratory data (12 months), active
medication and a list of the patient’s diagnoses. On the
remote server a clinical rule engine (CRE) evaluates the
provided information using the computerized decision
rule (see decision rule). The evaluation of the decision rule
may lead to a response in the form of a message. This
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exchange data) document and sent to the CDSS plugin
that has been installed on the GP’s computer. The plugin
reads the XML file and evaluates the contents. It extracts
the message title and displays part of the title in a thin
sidebar that is attached to the right side of the GP’s screen.
The GP can move the mouse cursor over the sidebar to
display the full message title. He or she can then choose to
either ignore the message by clicking on the ‘ignore’
button, or open the message by clicking anywhere on the
message title. When the message is opened, a report is
shown that displays the complete message, as well as the
findings that have led to the message, and a clickable link
to online background information. Upon first appearance,
the message title is displayed with a red background in the
sidebar, indicating the message is new. If the GP does not
interact with the message, the background will become or-
ange the next time the GP opens the electronic medical
record, indicating the message has been shown before but
not dealt with yet. When the GP changes the treatment
plan according to the guideline, the background will turn
green and the message title will be updated. This can hap-
pen without opening the message; that is, the GP might
already know that he or she needs to change the treatment
plan and doing so will also result in a green background
and updated message without the GP having to interact
with the CDSS plugin.
It is important to note that by using this procedure,
real-time feedback to the GP is provided. This means
that the GP will see a direct effect of every relevant ac-
tion he or she performs on the screen.
When analyzing baseline data to determine the current
proportion of correctly treated patients, we found that
recorded diagnoses of stroke were often incomplete or
inaccurate. Therefore, a single question was added to
the messages of the rule engine, which asks the GP for
the exact type of stroke if/when the International Classi-
fication of Primary Care (ICPC) [11] code for stroke
(K90) is found on the patient’s diagnoses list. The follow-
ing options will be presented to the GP: subarachnoid
hemorrhage (K90.01), hemorrhagic stroke (K90.02) and
ischemic stroke (K90.03). Once the question is answered,
the response is saved for future use and sent to the clin-
ical rule engine, where the entire decision rule can be
evaluated.
GPs who are allocated into the third group (interven-
tion 2) will not be able to ignore a message without pro-
viding justification. The GP is presented with several
predefined options and a free text field, which will allow
him or her to enter other explanations. The GP cannot
continue without answering this question. When the GP
tries to close the on-screen medical record without pro-
viding a reason for deviating from the advice, he or she
is reminded once more of the message and asked torespond. An independent adjudication committee will
value the legitimacy of the reasons provided to deviate
from the advised treatment and will contact GPs when
necessary.
Decision rule
The computerized decision rule is based on the Dutch
GP guideline for atrial fibrillation authored by the Dutch
College of General Practitioners [12]. This guideline uses
the CHADS2 score, a commonly used stroke risk strati-
fication scheme, which is calculated by assigning 1 point
each for the presence of congestive heart failure, hyper-
tension, age 75 years or older, and diabetes mellitus and
by assigning 2 points each for history of stroke or transi-
ent ischemic attack (TIA) [13].
The decision process consists of two phases:
1. The rule engine uses the decision rule to determine
the recommended treatment.
2. The rule engine compares the actual treatment to
the recommended treatment and generates the
message according to the result.
The first phase is a two-step procedure:
1. Determine whether contraindications for OAC are
present. If this is the case, antiplatelet drugs are the
preferred treatment.
2. Calculate the CHADS2 score. For scores of one and
lower, the preferred treatment is antiplatelet drugs;
for scores of two and higher, the preferred treatment
is OAC.
In the second phase, the recommended treatment is
compared to the actual treatment. A message is gener-
ated using this information (for example, ‘It is advised to
stop OAC and start antiplatelet drugs, due to the fact
that this patient has a CHADS2 score of 1’). There are a
total of 11 unique messages.
Baseline measurements
Baseline measurements will be performed to determine
the current proportion of patients with AF who are
treated in accordance with the guideline. These data will
be gathered by automatically evaluating the decision rule
on all patients in an anonymized copy of the GP’s EHR
databases before the start of the study.
Regulatory aspects
The medical ethics committee of the AMC deemed this
study exempt from ethical approval because the inter-
vention is a way of providing valid medical information
to GPs and does not change medical treatment or use
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tient data is used for analysis.
Every practice has provided written consent to partici-
pate in this study via a designated GP representative.
This trial is registered with the Dutch trial register
under number 3570.
Data collection
Whenever a message is shown, clicked, or ignored in the
CDSS plugin, this event is stored in a database along
with the current time and date. This will allow us to
analyze the way the system is used by the GPs and will
inform us about possible improvements that can be
made. The responses GPs give to the questions about
the type of stroke and the reason to ignore the message,
if any, are saved inside the XML document and sent
back to the remote server where the document is stored.
During the study, these XML files will be opened and
the responses will be extracted. To calculate adherence
rates we use anonymized patient data (disease list, medica-
tion, GP contacts, lab data), which are extracted directly
from the GP’s EHR databases.
Population
We will include GP practices in the Netherlands that use
the EHR for which the plugin was developed. Initially, we
will include every GP practice (18 clusters of GPs, with a
total of 35 GPs) that is part of the GAZO (a network of
GP practices in Amsterdam Southeast). Decision support
messages will be shown for every patient with atrial
fibrillation (both new and existing patients) who visits
the GP in his or her practice.
Sample size and analysis
A power analysis showed that 300 patients are needed
for a power of 0.8 when assuming a base adherence of
50%, an absolute effect size of 10% for intervention
group 2 and 20% for intervention group 3, with a test
significance level of 0.05. Because GPs are clustered for
randomization, a correction for these clustering effects
was introduced. For the cluster correction analysis, an
intraclass correlation of .1 was assumed, based on studies
using similar clustering [14]. This resulted in a required
sample size of approximately 500 patients to result in an
effective sample size of 300.
When data collection has been concluded, differences
in adherence percentages will be calculated per GP cluster.
A chi-square test will be used to compare the differences
in the three groups.
Outcomes
The primary outcome is the difference in the proportion
of patients with AF, treated in adherence to the guideline
between groups 1, 2 and 3.The secondary outcomes are the reasons GPs provide
for deviating from the guideline and the manner in which
they respond to required justification (intervention 2).
Discussion
This study will investigate the effectiveness of a decision
support system in primary care by implementing a system
that advises the general practitioner on antithrombotic
treatment for stroke prevention in patients with atrial fib-
rillation. We will use a novel system that does not rely on
pop-ups, but rather a sidebar that displays real-time mes-
sages concerning the actual patient, as studies have shown
this to be the most effective timing for a CDSS [10].
The success of the study depends on the ability of the
system to attract the attention of the GP and on the
quality of data stored in the EHR. One of our challenges
was finding the right mode of presentation, where mes-
sages are visible to the GP without interfering with their
usual workspace. This meant we had to investigate com-
puter use among GPs, especially which screen resolu-
tions were used and how much space was available on
their screen for our system. As it turned out, many GPs
were working on older systems with low-resolution
screens. We therefore had to adapt our system to actively
show part of the message titles, the rest being entirely vis-
ible on demand. We hope this mode of presentation will
not interfere significantly with the GP’s workspace, while
remaining visible enough for the GP to notice.
Guideline conversion
We could not fully convert the complete guideline into
our decision rule, as some elements were not available
as structured data in the GP’s EHR. For instance, the
finding ‘Fundus bleeds of the eye’ has no code that can
be used to identify it. Thus, we had to adapt our deci-
sion rule to work with the data that were available. Also,
severe renal failure and liver failure were not defined
with cut-off values, so we had to define these. These are
important factors to consider during future guideline
development, as decision support systems are expected
to play an increasingly important role in healthcare. The
recently introduced Logical Elements Rule Method
(LERM) could play an important role in ensuring
guideline-CDSS compatibility [15].
Reasons for deviation from the guideline
Based on findings in literature on this subject, we expect
GPs will have a number of valid reasons to provide treat-
ment different from the guideline [8,16]. These are
expected to be in the following categories: patient prefer-
ence, diagnostic uncertainty and contextual factors (for
example, medication prescribed by specialist). Almost all
the other reasons we expect GPs to report will be related
to incomplete registration. For instance, a contraindication
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the system’s advice, because the system checks for contra-
indications. Thus, the GP needs to update EHR to reflect
the latest clinical situation.
Effect size and reasons for non-adherence
We expect a 10% and 20% absolute effect size in interven-
tion groups A and B, respectively. We hypothesize that the
main reason for non-adherence is that there are too many
parameters in this guideline to be evaluated effectively dur-
ing a 10-minute visit. If a patient develops diabetes and
reaches the age of 75, that has an impact on multiple guide-
lines. It is virtually impossible to know every guideline by
heart, as there are currently one hundred Dutch GP guide-
lines, 10% of which are revised every year. Hence, the GP
will often not be aware that the patient in fact needs to re-
ceive OAC instead of aspirin due to the fact that his or her
CHADS2 score increased by two points.
Conclusion
This paper describes the protocol for a cluster random-
ized trial to study the effects of a clinical decision
support system in patients with atrial fibrillation. The
system is characterized by a non-interruptive presenta-
tion and real-time messages that are updated after each
action the GP performs (if the action is part of the deci-
sion rule). We expect an absolute effect size of 10 to
20%, because current guideline adherence is low (around
50%) and the guideline might be missed or is difficult to
evaluate during a patient visit in a busy practice.
Trial status
The CDSS plugin is currently being developed and tested.
It is expected to be finished in March 2013, at which time
a pilot period of one month will be started to identify any
problems. After 1 month we will start collecting data.
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